WOW 1-3: Thinly traded Cel-Sci (CELI), BioTime(BTIM) and Biomerica(BMRA) generated some sudden excitement last week. CELI gained $3.937 to $12.937 on 1.6 million shares traded on Tuesday, when it announced Japanese patent approval for its Multikine cytokine cocktail. Volume again ballooned on Thursday, to 2.7 million shares, after CEO Geert Kersten "had about 10 minutes of glory on CNBC" just prior to the opening.
CELI, which finished the week up $2.375 to $11.625, has made sweeping moves in recent weeks. It gained $3.125 to